Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call and Q&A reveal strong growth prospects, particularly in the U.S. market and minimally invasive segment, with raised guidance and strategic expansions. The optimism around Preserve and U.S. market penetration, coupled with improved margins and cash flow projections, supports a positive sentiment. However, some uncertainties in management's responses and lack of specific timelines slightly temper expectations, preventing a 'Strong positive' rating. Given the company's market cap, these factors suggest a likely positive stock movement of 2% to 8% in the short term.
Key Financial Performance
Fourth Quarter Revenue $64.6 million, an increase of 45.2% versus Q4 2024. The growth was driven by strong sales, including $17.3 million from Motiva revenue in the U.S.
2025 Total Revenue $211.1 million, an increase of 27.2% over 2024. This growth was attributed to the scaling of the business and operational leverage.
U.S. Motiva Revenue in 2025 $45.6 million, significantly exceeding expectations. The growth was due to high demand and market share gains in the U.S. augmentation market.
Gross Margin (Q4 2025) Exceeding 70% for the second consecutive quarter, up from 68.5% in Q4 2024. The improvement was driven by higher-margin sales in the U.S.
Net Loss from Operations (Q4 2025) $3.9 million, down 79% from Q4 2024. The reduction was due to strong sales and improved operational efficiency.
Adjusted EBITDA (Q4 2025) Positive $5.5 million, up from a negative $13.1 million in Q4 2024. This improvement was driven by strong sales and higher gross profit in the U.S.
Ending Cash Balance (2025) $75.6 million, an increase of $4.9 million in Q4 2025. The increase was due to reduced operating cash use and inflows from option exercises.
Gross Profit Margin (2025) Increased by 330 basis points compared to 2024, primarily due to higher-margin sales in the U.S.
SG&A Expenses (Q4 2025) $44.0 million, flat compared to Q4 2024, indicating controlled spending despite business growth.
R&D Expenses (Q4 2025) $5.4 million, reflecting continued investment in innovation and product development.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Motiva Revenue: Motiva revenue in the U.S. reached $45.6 million in 2025, significantly exceeding expectations. The product has achieved approximately 20% augmentation market share in the U.S. within one year of launch.
Preserve Minimally Invasive Platform: Preserve, a minimally invasive breast augmentation platform, has seen strong demand globally and is expanding the market. It is priced at twice the cost of traditional augmentation and has attracted patients who were not previously considering breast augmentation.
Innovation Pipeline: The company is working on new products like Mia, Ergonomix2, and GEM, which are expected to enter the U.S. market in the coming years.
U.S. Market Expansion: The U.S. market contributed 26.8% of global sales in Q4 2025, with Motiva implants gaining significant traction. The company onboarded over 1,500 accounts since late 2024 and plans to expand its U.S. sales force in 2026.
Global Market Performance: European direct markets grew over 20% for the third consecutive quarter, with strong performances in the U.K., Germany, and Spain. Latin America showed stable results in Brazil and strong growth in Argentina. APAC markets, including China, also showed improved performance.
Financial Performance: Q4 2025 revenue was $64.6 million, a 45.2% increase from Q4 2024. Gross margins exceeded 70% for the second consecutive quarter. Adjusted EBITDA was positive $5.5 million, up from a loss of $13.1 million in Q4 2024.
Cash Flow and Guidance: The company expects to be cash flow positive in 2026 and has no need for additional capital. Revenue guidance for 2026 is $264-$266 million, a 25% growth over 2025.
Reconstruction Market Entry: The company submitted Motiva implants to the FDA for approval in primary and revision breast reconstruction, which could double its addressable market in the U.S.
Management Transition: Raj Denhoy will transition to SVP Global Strategy, and Cassandra Harris will join as CFO to strengthen financial discipline and operational excellence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Delays: The company is awaiting FDA approval for Motiva implants in primary and revision breast reconstruction, as well as for small size submissions. Delays in these approvals could hinder market expansion and revenue growth.
Supply Chain Disruptions: The company operates in multiple global markets, including China, where distributor performance and timing of orders can fluctuate. Any disruptions in the supply chain could impact product availability and sales.
Competitive Pressures: While Motiva has gained significant market share, the company faces competition from established players with larger marketing budgets. Limited resources for marketing compared to competitors could affect brand visibility and adoption.
Economic Uncertainties: Global economic conditions, including fluctuations in foreign exchange rates, could impact revenue, particularly in distributor markets where timing of orders is variable.
Operational Scalability: The company is expanding its U.S. sales force and training more surgeons for new procedures like Preserve. Inefficiencies or delays in scaling operations could impact growth and profitability.
Market Adoption Risks: Although Motiva has seen strong adoption, the company is still in the early stages of U.S. market penetration. Slower-than-expected adoption rates could affect revenue projections.
Financial Risks: The company has outlined plans to achieve cash flow positivity in 2026 and meaningful earnings in 2027. Any deviation from these financial targets could impact investor confidence and funding options.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects revenue to be between $264 million and $266 million, representing a growth of 25.1% to 26% over 2025.
Revenue Growth Projections for 2027: The company anticipates at least 25% growth in 2027, similar to 2026.
Gross Margin Projections: Gross margins are expected to increase by 200 to 300 basis points in 2026.
Cash Flow Projections: The company expects to achieve positive cash flow in 2026 and remain cash flow positive throughout 2027.
U.S. Market Contribution: The U.S. market is expected to exceed 30% of overall sales in 2026, up from approximately 22% in 2025.
Operating Expenses: Operating expenses are projected to be approximately $195 million to $200 million in 2026.
Minimally Invasive Platform Growth: Global demand for the minimally invasive platform is expected to exceed $30 million in 2026, continuing as a key growth driver in subsequent years.
Preserve Product Launch: The full launch of the Preserve product is planned for March 2026, with at least 200 plastic surgeons trained by the end of the year.
Reconstruction Market Expansion: The company submitted Motiva implants to the FDA for approval in primary and revision breast reconstruction, which could double the total addressable market in the U.S.
Innovation Pipeline: Future product launches include Mia, Ergonomix2, and GEM, which are expected to drive growth in the coming years.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the optimism and trajectory of the market with minimally invasive offerings like Preserve and Mia?
A:The minimally invasive platform is showing extremely positive results, especially in OUS markets and early U.S. experiences. Benefits like no general anesthesia, smaller scars, and faster recovery resonate with patients. Surveys indicate 14% of patients who opted for breast augmentation were influenced by Preserve. The company estimates over $30 million in revenue from this segment this year and sees it as a key driver for future growth.
Q:Where are you sourcing new sales representatives, and how do you expect their productivity to ramp up?
A:The company is focused on hiring experienced reps with strong industry reputations and track records. Many see Establishment Labs as an attractive opportunity. This approach is expected to drive success in the U.S. market and beyond.
Q:How do you plan to launch into the U.S. reconstruction market upon FDA approval?
A:The company plans to expand its sales force with a mix of hybrid and dedicated reps for larger hospital networks. They aim to ensure proper coverage and sales support. With Flora already in over 200 accounts, the ramp-up is expected to be quicker.
Q:Was the strong international growth this quarter due to one-offs or underlying procedure growth?
A:The growth reflects underlying procedure growth and strategic focus on direct markets. There were no significant stocking orders; the demand is stable, and execution has been strong.
Q:What is the outlook for breast augmentation markets in the U.S. and internationally?
A:The U.S. market is healthy, with increased interest in breast augmentation procedures driven by company activities. Internationally, distributor markets have shown over 20% growth for several quarters. China is improving after management focus, and overall demand remains strong.
Q:What is the potential revenue contribution of Preserve by 2027-2028, and how will it impact gross margins?
A:Preserve could potentially account for 50% of U.S. revenues by 2027-2028. It generates twice the revenue per case compared to implants alone and has higher margins, providing a significant tailwind for gross margins.
Q:What is the long-term outlook for U.S. market share gains and growth trajectory?
A:The company expects strong momentum in 2026, driven by increased account penetration, new accounts, additional reps, and product launches like Preserve. They aim to dominate the U.S. market sooner than initially planned.
Q:Are there any gaps in the portfolio that the company plans to address?
A:The company is exploring business development and portfolio expansion opportunities, with a focus on prioritizing innovation and go-to-market strategies.
Q:What contribution from pipeline products like small sizes and reconstruction is factored into the 2026 guidance?
A:Reconstruction is expected to contribute in 2027 and beyond. Preserve has significant upside potential and is expected to drive business growth in 2026.
Q:What is the expected cadence of operating expenses in 2026?
A:Operating expenses will not be linear. The first quarter may be below trend, with spending picking up in the middle and back half of the year. Incremental investments for reconstruction will be well below the revenue opportunity it represents.
Q:What seasonality is expected in revenue guidance for 2026?
A:The U.S. is expected to grow sequentially, with modest growth in Q1 and stronger growth in subsequent quarters. International markets will follow a typical seasonal pattern, with a strong finish to the year.
Q:What is the penetration level in U.S. accounts, and how will it evolve in 2026?
A:Penetration is still low in many accounts, especially newer ones. The focus in 2026 will be on increasing penetration in existing accounts while adding new ones.
Q:What are the expectations for the China market in 2026 and beyond?
A:China remains a large market with significant potential. Progress has been made in the back half of the year, and the company expects to achieve dominant market share in the future.
Q:How much of U.S. growth in 2026 will come from volume versus ASP expansion?
A:The majority of growth will come from unit growth and market penetration. Preserve will contribute to ASP expansion, but the primary driver is taking share from incumbents.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timeline for FDA approval of reconstruction products and the precise impact of Preserve on 2026 revenue. They also used vague language when discussing the cadence of operating expenses and the timeline for achieving dominant market share in China.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brazil Argentina
CFO
ESTA
Establishment Labs
FDA approval
Patients
Sales United
addition
adoption
anesthesia
augmentation market
augmentation procedure
benefit augmentation
case surgeon
coast
competitor
consumer
demand expectation
dollar
era transparency
idea
momentum
need
opportunity
oversight
paradigm
patient breast
patient doctor
practice
price point
rate
role
secret
surgeon brand
surgeon patient
survey surgeon
transition
value
volume
website
win
ESTA Transcript
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance with a 25% revenue increase and a significant improvement in gross margin to 70%. The company turned a net loss into a net income, and operating cash flow rose by 50%. These positive financial metrics, coupled with the anticipation of future growth and product launches, suggest a positive sentiment. However, the absence of strategic and operational updates, along with management's caution on risks, tempers expectations slightly. Given the company's small-cap status, the stock is likely to see a positive movement of 2% to 8%.
Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call and Q&A reveal strong growth prospects, particularly in the U.S. market and minimally invasive segment, with raised guidance and strategic expansions. The optimism around Preserve and U.S. market penetration, coupled with improved margins and cash flow projections, supports a positive sentiment. However, some uncertainties in management's responses and lack of specific timelines slightly temper expectations, preventing a 'Strong positive' rating. Given the company's market cap, these factors suggest a likely positive stock movement of 2% to 8% in the short term.
Establishment Labs Holdings Inc. (ESTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Establishment Labs Holdings Inc. (ESTA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial performance with record high revenue, positive EBITDA, and increased cash position. The company raised its revenue guidance and expects continued growth in the U.S. and international markets. The Q&A session confirmed positive momentum, strong market share goals, and strategic expansions. Despite some uncertainties, the overall sentiment is very positive, especially with significant growth expectations and strategic initiatives in place. Given the company's small-cap status, a strong positive stock price reaction is anticipated.
ESTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
